• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Zevra Therapeutics, Inc. - Common Stock (NQ: ZVRA )

    6.270 -0.070 (-1.10%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 367,638
    Open 6.300
    Bid (Size) 6.270 (1)
    Ask (Size) 6.450 (2)
    Prev. Close 6.340
    Today's Range 6.190 - 6.440
    52wk Range 3.890 - 7.280
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Insiders Buying Zevra Therapeutics And 1 Other Stock
    Via Benzinga

    Performance

    YTD
    -8.20%
    -8.20%
    1 Month
    +39.33%
    +39.33%
    3 Month
    +36.90%
    +36.90%
    6 Month
    +5.56%
    +5.56%
    1 Year
    +31.45%
    +31.45%

    More News

    Read More
    Insiders Buying Barnes & Noble Education And 2 Other Stocks
    Via Benzinga
    SmallCap Tech/Biotech Stocks July/Aug 2024: ZVSA, DYAI, ZVRA, PRSO, RLMD, VTAK, ENTO, INBS, KAVL
    Via AB Newswire
    FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base
    Via Benzinga
    Exposures Product Safety
    Zevra Therapeutics: Q4 Earnings Insights
    Via Benzinga
    Earnings Outlook For Zevra Therapeutics
    Via Benzinga
    Zevra Therapeutics's Earnings: A Preview
    Via Benzinga
    Zevra Therapeutics's Earnings: A Preview
    Via Benzinga
    ZVRA Stock Earnings: Zevra Therapeutics Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Zevra Therapeutics, Inc. (NASDAQ: ZVRA) Letter to Stakeholders Looks Like Launch Code to Drive Value
    Via Investor Brand Network
    ZEVRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Zevra Therapeutics, Inc. on Behalf of Zevra Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Zevra Therapeutics, Inc. (ZVRA)
    From Kirby McInerney LLP
    Via GlobeNewswire
    ZVRA Stock Earnings: Zevra Therapeutics Misses EPS, Beats Revenue for Q4 2023
    Via InvestorPlace
    Earnings Scheduled For March 28, 2024
    Via Benzinga
    Microsoft To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Thursday
    Via Benzinga
    BioMedNewsBreaks – Zevra Therapeutics Inc. (NASDAQ: ZVRA) Resubmits Arimoclomol New Drug Application to the FDA
    Via Investor Brand Network
    Exposures Product Safety
    InvestorNewsBreaks — Zevra Therapeutics Inc. (NASDAQ: ZVRA) Names New President, CEO and Director
    Via Investor Brand Network
    Topics Retirement
    Exposures Pension
    Earnings Scheduled For November 7, 2023
    Via Benzinga
    Health Care Company Zevra Therapeutics Announces Merger With Acer Therapeutics
    Via Benzinga
    Why Is Acer Therapeutics Stock Trading Higher Today?
    Via Benzinga
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Acer Therapeutics Inc. (Nasdaq - ACER), Sovos Brands, Inc. (Nasdaq - SOVO), Computer Task Group, Incorporated (Nasdaq - CTG), Decibel Therapeutics, Inc. (Nasdaq -
    From Brodsky & Smith LLC
    Via GlobeNewswire
    Why Is Acer Therapeutics (ACER) Stock Up 85% Today?
    Via InvestorPlace
    Earnings Scheduled For August 14, 2023
    Via Benzinga
    Earnings Scheduled For May 15, 2023
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.